
Current Price | $26.13 | Mkt Cap | $469.8M |
---|---|---|---|
Open | $25.74 | P/E Ratio | 0.00 |
Prev. Close | $26.13 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $25.68 - $26.87 | Volume | 171,214 |
52-Wk Range | $21.33 - $99.18 | Avg. Daily Vol. | 189,807 |
Current Price | $26.13 | Mkt Cap | $469.8M |
---|---|---|---|
Open | $25.74 | P/E Ratio | 0.00 |
Prev. Close | $26.13 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $25.68 - $26.87 | Volume | 171,214 |
52-Wk Range | $21.33 - $99.18 | Avg. Daily Vol. | 189,807 |
The best Bull and Bear pitches based on recency and number of recommendations.
Read the most recent pitches from players about OPRX.
Recs
Doctors barely have time to devote to their patients. Anything to increase their efficiency will help increase available doctor to patient face time.
Recs
Huge market opportunity with above market revenue growth.
Recs
Doctors do want to learn about new drugs and devices in their field, but they are so overworked that dealing with sales rep is a nuisance that is tolerated at best because of the goodies they sometimes bring. Electronic health records are the future. Putting these two together, advertising new drugs and devices to doctors over EHR sounds like a major improvement on the status quo, a win for the doctors who can stay up to date and a win for the pharma and biotech companies who get to sell their new products.
Find the members with the highest scoring picks in OPRX.
fillmorea (< 20) Score: +64.89
The Score Leader is the player with the highest score across all their picks in OPRX.
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
---|---|---|---|---|---|---|---|---|---|---|
ranaxy | 74.15 | 2/3/2022 |
![]() |
5Y | $42.15 | -38.01% | -13.08% | -24.93 | 0 Comment | |
![]() |
FVelociraptor | 92.70 | 1/7/2021 |
![]() |
5Y | $37.79 | -30.85% | +3.53% | -34.39 | 1 Comment |
yoman | < 20 | 1/12/2021 |
![]() |
5Y | $38.50 | -32.13% | +2.77% | -34.90 | 0 Comment | |
squidulin | < 20 | 7/29/2021 |
![]() |
5Y | $54.12 | -51.72% | -11.69% | -40.03 | 0 Comment | |
dvanhoof | < 20 | 3/29/2021 |
![]() |
5Y | $47.05 | -44.46% | -1.27% | -43.19 | 0 Comment | |
MightyPeepAnt | 55.17 | 8/19/2021 |
![]() |
5Y | $57.43 | -54.50% | -10.75% | -43.75 | 0 Comment | |
VetteNV | < 20 | 1/19/2021 |
![]() |
3Y | $44.43 | -41.19% | +2.92% | -44.11 | 0 Comment | |
jswinkler16 | < 20 | 3/26/2021 |
![]() |
5Y | $47.20 | -44.64% | -0.40% | -44.24 | 1 Comment | |
ChiefRuby | < 20 | 1/26/2021 |
![]() |
5Y | $47.40 | -44.87% | +1.17% | -46.05 | 0 Comment | |
StockBeagle79 | < 20 | 2/1/2021 |
![]() |
5Y | $45.75 | -42.89% | +3.65% | -46.53 | 1 Comment |
See what the Wall Street professionals think, according to their public statements and filings.